Big Changes Are Coming in Hepatitis C, Current Gastroenterology Reports, vol.139, issue.Suppl 1, pp.1906-1914, 2011. ,
DOI : 10.1007/s11894-010-0153-9
New direct-acting antivirals' combination for the treatment of chronic hepatitis C, Liver International, vol.376, pp.68-77, 2011. ,
DOI : 10.1111/j.1478-3231.2010.02411.x
Telaprevir for Previously Treated Chronic HCV Infection, New England Journal of Medicine, vol.362, issue.14, pp.1292-1303, 2010. ,
DOI : 10.1056/NEJMoa0908014
HCV respond-2 final results: high sustained virologic response among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when re-treated with boceprevir plus pegintron (peginterferon alfa-2b)/ribavirin, Hepatology, vol.52, p.430, 2010. ,
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection, New England Journal of Medicine, vol.360, issue.18, pp.1839-1850, 2009. ,
DOI : 10.1056/NEJMoa0807650
Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PEGIFN/RBV for up to 28 days in treatment naïve , genotype 1 HCV subjects, Hepatology, vol.52, p.400, 2010. ,
57 ACTIVITY OF TELAPREVIR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 2 AND 3 HEPATITIS-C PATIENTS: FINAL RESULTS OF STUDY C209, Journal of Hepatology, vol.52, p.27, 2010. ,
DOI : 10.1016/S0168-8278(10)60059-1
Combination therapy with BMS-790052 and BMS-650032 alone or with PegIFN/RBV results in undetectable HCV RNA through 12 weeks of therapy in HCV genotype 1 null responders, Hepatology, vol.52, p.877, 2010. ,